Assessing glycemic and weight-lowering potential of oral semaglutide in type 2 diabetes compared to other GLP-1 receptor agonists in Indian context

被引：0
|
作者：
Singh, Awadhesh Kumar [1 ,2 ,3 ]
Chawla, Rajeev [4 ]
机构：
[1] GD Hosp & Diabet Inst, Kolkata 700013, West Bengal, India
[2] Horizon Multispecial Hosp, Kolkata, West Bengal, India
[3] Sun Valley Hosp & Diabet Res Ctr, Gauhati, Assam, India
[4] North Delhi Diabet Ctr, New Delhi, India
来源：
INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES | 2024年 / 44卷 / 02期
关键词：
ONCE-WEEKLY SEMAGLUTIDE; OPEN-LABEL; PHASE; 3A; CARDIOVASCULAR OUTCOMES; JAPANESE PATIENTS; ADD-ON; EFFICACY; SAFETY; DULAGLUTIDE; METFORMIN;
D O I：
10.1007/s13410-024-01337-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：211 / 215
页数：5
相关论文
共 50 条
  • [21] The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
    Thomas, Merlin C.
    DIABETES & METABOLISM, 2017, 43 : 2S20 - 2S27
  • [22] Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
    Ostergaard, L.
    Frandsen, Christian S.
    Madsbad, S.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (02) : 241 - 265
  • [23] The role of GLP-1 receptor agonists in managing type 2 diabetes br
    Nachawi, Noura
    Rao, Pratibha P. R.
    Makin, Vinni
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2022, 89 (08) : 457 - 464
  • [24] GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review
    Alfaris, Nasreen
    Waldrop, Stephanie
    Johnson, Veronica
    Boaventura, Brunna
    Kendrick, Karla
    Stanford, Fatima Cody
    ECLINICALMEDICINE, 2024, 75
  • [25] Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review
    Stretton, Brandon
    Kovoor, Joshua
    Bacchi, Stephen
    Chang, Shantel
    Ngoi, Benjamin
    Murray, Tess
    Bristow, Thomas C.
    Heng, Jonathan
    Gupta, Aashray
    Ovenden, Christopher
    Maddern, Guy
    Thompson, Campbell H.
    Heilbronn, Leonie
    Boyd, Mark
    Rayner, Christopher
    Talley, Nicholas J.
    Horowtiz, Michael
    INTERNAL MEDICINE JOURNAL, 2023, 53 (08) : 1311 - 1320
  • [26] An overview of new GLP-1 receptor agonists for type 2 diabetes
    Tomlinson, Brian
    Hu, Miao
    Zhang, Yuzhen
    Chan, Paul
    Liu, Zhong-Min
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (02) : 145 - 158
  • [27] GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Banerjee, Mainak
    Pal, Rimesh
    Mukhopadhyay, Satinath
    Nair, Kirthana
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (07) : 1806 - 1812
  • [28] Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus
    Cowart, Kevin
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (05) : 478 - 485
  • [29] A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin
    Witkowski, Michal
    Wilkinson, Lars
    Webb, Neil
    Weids, Alan
    Glah, Divina
    Vrazic, Hrvoje
    DIABETES THERAPY, 2018, 9 (03) : 1233 - 1251
  • [30] Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
    Gül Bahtiyar
    Jean Pujals-Kury
    Alan Sacerdote
    Current Diabetes Reports, 2018, 18
12345